Recombinant Factor C Endotoxin Detection Reagent: Key Points from Method Innovation to Quality Control Practice

Method Principle and Specificity Advantages

Recombinant C-factor endotoxin detection reagents use gene recombination technology to express C-factor from the horseshoe crab coagulation cascade, bypassing potential interference from other coagulation factors in traditional horseshoe crab reagents. This reagent produces a fluorescent signal only in response to the active component of endotoxin and does not respond to non-endotoxin substances such as β-glucan; therefore, it has good methodological specificity in the detection of samples with a high risk of fungal polysaccharide contamination. Compared with kinetic chromogenic methods or gel-clot methods, its reaction system is simpler, and inter-batch variation control is also clearer.

Applicable Scenarios and Common Specifications

This reagent is generally suitable for endotoxin detection in process water, APIs, injectable intermediates, and final products, and can also be used with a microplate reader for quantitative analysis. Common specifications include lyophilized powder forms and pre-formulated microplate forms, and users need to choose according to laboratory throughput and testing frequency. It is worth noting that reagents from different manufacturers may differ in sensitivity range, incubation time, and fluorescence reading conditions, and systematic suitability testing must be performed according to the manufacturer's instructions during method transfer.

Method Validation and Interference Assessment

Before introducing the recombinant C-factor method, laboratories should carry out validation of items such as standard curve reliability, precision, accuracy, and detection limit in accordance with the general requirements of pharmacopoeias for quantitative methods. Because recombinant C-factor does not undergo traditional cascade amplification, the inhibitory effects of certain excipient components in samples on enzyme activity may be inconsistent with those of horseshoe crab reagents; therefore, spike recovery tests must be performed for specific samples, and reasonable dilution factors and neutralization strategies must be established. Interference testing should cover the maximum-concentration batches in actual production and must evaluate factors such as pH, salt concentration, and chelating agents.

Risk Control and Compliance Considerations in Use

Although recombinant C-factor technology avoids dependence on horseshoe crab resources, it remains relatively sensitive to the cleanliness of the operating environment, especially because exogenous endotoxin contamination may cause false-positive results. Laboratory consumables should be selected at low-endotoxin levels, and contamination sources such as saliva and skin contact should be avoided during operation. In addition, if a company has already accumulated historical batch release data using the gel-clot method, when switching to the recombinant C-factor method, it is recommended to conduct parallel comparison and communicate method change information with regulatory agencies or customers in advance. Reagent storage should strictly follow cold-chain requirements to avoid repeated freeze-thaw cycles that lead to decreased enzyme activity.

Summary

Recombinant C-factor endotoxin detection reagents provide the pharmaceutical industry with an endotoxin quantification tool that does not rely on animal-derived sources. Their methodological advantages coexist with usage thresholds, and laboratories should comprehensively evaluate sample matrices, validation costs, and regulatory acceptance when introducing them to ensure the reliability of test results and data integrity.